Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Jassal, Bijay, 2020-05-22

Class:IdInstanceEdit:9689903
_displayNameJassal, Bijay, 2020-05-22
_timestamp2020-05-22 08:41:44
author[Person:73447] Jassal, Bijay
dateTime2020-05-22 08:41:00
(created)[Person:9689860] Rutgeerts, Paul
[Person:9689861] Cortot, Antoine
[Person:9689862] Cheng, May
[Person:9689863] Pachlopnik Schmid, Jana
[Person:9689864] Lonovics, J
[Person:9689865] Zákuciová, M
[Person:9689866] Lounder, Dana T
[Person:9689867] Landolfi, Nicholas F
[Person:9689868] Edmundson, Allen B
[Person:9689869] Jordan, Michael B
List all 44 refering instances
(modified)[LiteratureReference:9689678] Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms
[LiteratureReference:9689682] Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice
[LiteratureReference:9689683] Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
[LiteratureReference:9689687] Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections
[LiteratureReference:9689690] Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
[Change default viewing format]
No pathways have been reviewed or authored by Jassal, Bijay, 2020-05-22 (9689903)
Follow Reactome